(050) RESULTS FROM A PATIENT SURVEY EXPLORING THE EFFECTS OF FLIBANSERIN IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) BASED ON TREATMENT DURATION
Bibliographic record
Abstract
Abstract Introduction Flibanserin is approved in the US to treat premenopausal women and in Canada for pre- and naturally postmenopausal women ≤60 years with acquired, generalized HSDD. Improvement in symptoms can emerge as early as 4 weeks after starting flibanserin but may take up to 8 weeks of daily use. There is limited real-world data exploring patient response to flibanserin based on treatment duration. Objective Analyze results from a patient survey to explore the effects of flibanserin based on treatment duration Methods Women aged ≥18 years with HSDD prescribed flibanserin via a telehealth platform were invited to participate. Invitational emails containing a secure study link, generated via the platform, were sent 60 days after an initial or renewed flibanserin prescription during the study period (August 1, 2022, to September 30, 2023). The first question screened for current flibanserin use. Women who had discontinued treatment exited the survey. Questions captured changes in HSDD symptoms, partner relationships, weight, sleep, and mood since starting flibanserin. Five multiple-choice response options accompanied each question. A response of “improved a lot” or “improved a little” was categorized as “Benefit”, and a response of “no change,” “worsened a little,” or “worsened a lot” was categorized as “No Benefit”. Results were analyzed descriptively based on treatment duration. Results Invitational emails were sent to 17,113 women. Of 638 women who accessed the link, 199 had discontinued flibanserin and exited the survey, and 439 completed the survey (mean age 40 [range 21-66] years). Duration of therapy was <1 month, 1-2 months, and >2 months in 44, 231, and 164 women, respectively. The percentage of women reporting benefits in HSDD symptoms and partner relationships consistently increased with longer treatment. For weight loss and mood, there was a trend of more women experiencing benefit with continued use. For those who experienced improved sleep quality, the improvement began early (<1 month); the percentage of respondents experiencing benefit or lack of benefit in sleep did not change over prolonged use. Conclusions Daily flibanserin use may increase interest in sexual activity and improve partner relationships in certain women. These improvements may emerge as early as one month following treatment initiation. However, consistent with previous findings, some women may need longer treatment durations. As expected, effects on weight and mood may take longer to emerge. The impact on sleep quality may be apparent early in treatment and remain consistent with continued use. Disclosure Yes, this is sponsored by industry/sponsor: Sprout Pharmaceuticals, Inc Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: Sprout Pharmaceuticals, Inc.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".